Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: A phase 2 Cancer and Leukemia Group B Study (CALGB 10503)

Leukemia

Volumn 31, Issue 1, 2017, Pages 34-39

  Blum, W ^a   Sanford, B L ^b   Klisovic, R ^a   Deangelo, D J ^c   Uy, G ^d   Powell, B L ^e   Stock, W ^f   Baer, M R ^g   Kolitz, J E ^h   Wang, E S ⁱ   Hoke, E ^b   Mrozek K ^a   Kohlschmidt, J ^a,b   Bloomfield, C D ^a   Geyer, S ^j   Marcucci, G ^k   Stone, R M ^c   Larson, R A ^f  

^a OHIO STATE UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d WASHINGTON UNIVERSITY   (United States)

^e WAKE FOREST BAPTIST HEALTH   (United States)

^f UNIVERSITY OF CHICAGO   (United States)

^g UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^h DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

ⁱ ROSWELL PARK CANCER INSTITUTE   (United States)

^j UNIVERSITY OF SOUTH FLORIDA   (United States)

^k CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BUSULFAN; CYTARABINE; DAUNORUBICIN; DECITABINE; ETOPOSIDE; AZACITIDINE;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ANEMIA; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD CELL COUNT; BONE MARROW SUPPRESSION; CANCER PATIENT; CANCER SURVIVAL; CONSOLIDATION CHEMOTHERAPY; CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; DRUG MEGADOSE; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; INDUCTION CHEMOTHERAPY; INFECTION; LEUKEMIA REMISSION; MAINTENANCE THERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; YOUNG ADULT; ADOLESCENT; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; FEMALE; LEUKEMIA, MYELOID, ACUTE; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; MORTALITY; PROCEDURES; REMISSION; SURVIVAL RATE;

ADOLESCENT; ADULT; AZACITIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; REMISSION INDUCTION; SURVIVAL RATE; YOUNG ADULT;

EID: 84990212570     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2016.252     Document Type: Article

References (37)

1. Champlin R, Jacobs A, Gale RP, Boccia R, Elashoff R, Foon K et al. Prolonged survival in acute myelogenous leukaemia without maintenance chemotherapy. Lancet 1984; 1: 894-896
2. Raza A, Preisler HD, Browman GP, Larson RA, Rustum YM, Goldberg J et al. Long-term outcome of patients with acute myelogenous leukemia: the role of maintenance therapy, consolidation therapy and the predictive value of two in vitro assays. Leuk Lymphoma 1993; 10: 57-66
3. Sauter C, Berchtold W, Fopp M, Gratwohl A, Imbach P, Maurice P et al. Acute myelogenous leukaemia: maintenance chemotherapy after early consolidation treatment does not prolong survival. Lancet 1984; 1: 379-382
4. Büchner T, Berdel WE, Schoch C, Haferlach T, Serve HL, Kienast J et al. Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol 2006; 24: 2480-2489
5. Büchner T, Hiddemann W, Berdel WE, Wörmann B, Schoch C, Fonatsch C et al. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. J Clin Oncol 2003; 21: 4496-4504
6. Santini V, Kantarjian HM, Issa JP. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med 2001; 134: 573-586
7. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol 2002; 20: 2429-2440
8. Kantarjian H, Issa J-PJ, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106: 1794-1803
9. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223-232
10. Fenaux P, Mufti GJ, Hellström-Lindberg E, Santini V, Gattermann N, Germing U et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010; 28: 562-569
11. Issa J-PJ, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004; 103: 1635-1640
12. Blum W, Garzon R, Klisovic RB, Schwind S, Walker A, Geyer S et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci USA 2010; 107: 7473-7478
13. Cashen AF, Schiller GJ, O'Donnell MR, DiPersio JF. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol 2010; 28: 556-561
14. Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 2012; 30: 2670-2677
15. Boumber Y, Kantarjian H, Jorgensen J, Wen S, Faderl S, Castoro R et al. A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission [letter]. Leukemia 2012; 26: 2428-2431
16. Mrózek K, Prior TW, Edwards C, Marcucci G, Carroll AJ, Snyder PJ et al. Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2001; 19: 2482-2492
17. Linker CA, Ries CA, Damon LE, Sayre P, Navarro W, Rugo HS et al. Autologous stem cell transplantation for acute myeloid leukemia in first remission. Biol Blood Marrow Transplant 2000; 6: 50-57
18. Linker CA, Owzar K, Powell B, Hurd D, Damon LE, Archer LE et al. Auto-SCT for AML in second remission: CALGB study 9620. Bone Marrow Transplant 2009; 44: 353-359
19. Mrózek K, Carroll AJ, Maharry K, Rao KW, Patil SR, Pettenati MJ et al. Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: the Cancer and Leukemia Group B experience. Int J Oncol 2008; 33: 239-244
20. Whitman SP, Archer KJ, Feng L, Baldus C, Becknell B, Carlson BD et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a Cancer and Leukemia Group B study. Cancer Res 2001; 61: 7233-7239
21. Thiede C, Steudel C, Mohr B, Schaich M, Schäkel U, Platzbecker U et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002; 99: 4326-4335
22. Marcucci G, Maharry K, Radmacher MD, Mrózek K, Vukosavljevic T, Paschka P et al. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B study. J Clin Oncol 2008; 26: 5078-5087
23. Becker H, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Margeson D et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated geneand microRNA-expression signatures: a Cancer and Leukemia Group B study. J Clin Oncol 2010; 28: 596-604
24. Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453-474
25. Cassileth PA, Lynch E, Hines JD, Oken MM, Mazza JJ, Bennett JM et al. Varying intensity of postremission therapy in acute myeloid leukemia. Blood 1992; 79: 1924-1930
26. Löwenberg B, Suciu S, Archimbaud E, Haak H, Stryckmans P, de Cataldo R et al. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy-the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report of the European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group randomized phase III study AML-9. J Clin Oncol 1998; 16: 872-881
27. Petersdorf SH, Kopecky KJ, Slovak M, Willman C, Nevill T, Brandwein J et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood 2013; 121: 4854-4860
28. Löwenberg B, Beck J, Graux C, van Putten W, Schouten HC, Verdonck LF et al. Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. Blood 2010; 115: 2586-2591
29. Kolitz JE, George SL, Benson DM Jr, Maharry K, Marcucci G, Vij R et al. Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808. Cancer 2014; 120: 1010-1017
30. Baer MR, George SL, Caligiuri MA, Sanford BL, Bothun SM, Mrózek K et al. Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B study 9720. J Clin Oncol 2008; 26: 4934-4939
31. Cortes JE, Kantarjian HM, O'Brien S, Giles F, Keating MJ, Freireich EJ et al. A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission. Cancer 1999; 85: 1506-1513
32. Blaise D, Attal M, Reiffers J, Michallet M, Bellanger C, Pico JL et al. Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remission. Eur Cytokine Netw 2000; 11: 91-98
33. Khatri VP, Baiocchi RA, Bernstein ZP, Caligiuri MA. Immunotherapy with low-dose interleukin-2: rationale for prevention of immune-deficiency-associated cancer. Cancer J Sci Am 1997; 3(Suppl 1): S129-S136
34. Stone RM, DeAngelo DJ, Janosova A, Galinsky I, Canning C, Ritz J et al. Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission. Am J Hematol 2008; 83: 771-777
35. Brune M, Castaigne S, Catalano J, Gehlsen K, Ho AD, Hofmann WK et al. Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. Blood 2006; 108: 88-96
36. Buyse M, Squifflet P, Lange BJ, Alonzo TA, Larson RA, Kolitz JE et al. Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia. Blood 2011; 117: 7007-7013
37. Liu S, Shen T, Huynh L, Klisovic MI, Rush LJ, Ford JL et al. Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia. Cancer Res 2005; 65: 1277-1284.